

Table S1 Baseline characteristics of patients referred to palliative care compared to those not referred

	Total (n=384)	Outpatient referred to PC (n=126)	Inpatients referred to PC (n=72)	Not referred to PC (n=186)	*p-value
ILD	281 (73%)	102 (81%)	62 (86%)	117 (63%)	<0.001
COPD	103 (27%)	24 (19%)	10 (14%)	69 (37%)	
Male	230 (60%)	59 (47%)	47 (65%)	124 (67%)	<0.001
Age, years (mean ± SD)	60 ± 9	61 ± 9	61 ± 9	60 ± 8	0.32
Body Mass Index (kg/m ²)	25.7 ± 4.2	25.7 ± 3.9	25.5 ± 4.5	25.7 ± 4.3	0.93
Time on List (days)	104 [41-229]	160 [83-306]	65 [18-146]	88 [28-194]	<0.001
Status at Listing					
Status 1	169 (44%)	60 (48%)	19 (26%)	90 (48%)	
Status 2	174 (45%)	62 (49%)	38 (53%)	74 (40%)	
Status 3	35 (9.1%)	4 (3%)	15 (21%)	16 (8.6%)	
FEV ₁ at listing – COPD patients (% n=102)	22 ± 12	22 ± 8	19 ± 4	23 ± 14	0.57
FVC at listing – ILD patients (% n=270)	47 ± 15	46 ± 12	46 ± 16	49.0 ± 16	0.43
6MWD at listing (m, n=363)	307 [240-381]	330 [252-404]	262 [175-352]	305 [240-371]	0.07
6MWD at listing (%predicted; n=360)	58 [43-72]	61 [48-81]	49 [34-64]	58 [43-71]	0.04

*, P value indicates comparison between outpatients referred to PC, and those not referred to PC. Data presented as mean ± SD, median [Interquartile range], and n (%). Missing data is reflected by numbers available for the row. COPD, Chronic obstructive pulmonary disease; FEV₁, forced expiratory volume in one second; FVC = Forced Vital Capacity; FiO₂ = Fraction of inspired oxygen; ILD = Interstitial lung disease; PC, palliative care; 6MWD, 6-minute walk distance.




Figure S1 Mean change in Edmonton Symptom Assessment Score domains pre-transplant among ILD and COPD patients. COPD, Chronic obstructive pulmonary disease; ESAS, Edmonton symptom assessment score; ILD, Interstitial lung disease.




Figure S2 Edmonton Symptom Assessment Score for ILD and COPD patients in the Pre-Transplant Period. Bold lines indicate the average score for entire ILD or COPD by visit, whereas thin lines represent the trajectory of individual patients. Average score was derived by calculating all available scores by domain and determining proportion of all available domains (i.e., missing data was not included in calculation of total average score). COPD, Chronic obstructive pulmonary disease; ESAS, Edmonton symptom assessment score; ILD, Interstitial lung disease; PC, Palliative care.




Figure S3 Peak opioid total daily dose pre-transplant plotted as a percent of total number of recorded opioid doses. All values recorded in morphine equivalent (mg). COPD (n=23); ILD (n=97). As needed indicates those who were prescribed standard 2.5-5 mg q4h PRN dose. In these patients, either a follow record was not available to ascertain exact dose being taken, or when follow up occurred, a change in dose was not documented in the palliative care visit note.




Figure S4 Assessment of top-three Edmonton Symptom Assessment System score domains stratified based on Six-Minute Walk Distance (6MWT), Supplemental Oxygen Use and Respiratory Exacerbation History. Participants were stratified into two groups based on whether (A) they achieved greater or less than the median 6-minute walk distance of all participants, or (B) they required greater than or less than the median oxygen requirement of all participants, or (C) they experienced a respiratory exacerbation during the study period or not. All values rounded to the nearest point. 6MWT, 6-minute walk test.

Table S2 Comparison of Edmonton Symptom Assessment System scores among ILD patients stratified by pre-transplant outcome

Domain (median, IQR)	Total Cohort ILD (n=102)	ILD Delisted/Died (n=12)	ILD transplanted (n=90)	P-value
Pain	1.5 [0-4]	0 [0-4]	1.6 [0-4]	0.50
Fatigue	6.0 [4-8]	5 [5-8]	6 [4-8]	0.42
Nausea	0 [0-1]	0 [0-4]	0 [0-1]	0.66
Depression	1 [0-4]	4.5 [0-7]	1 [0-3]	0.04
Anxiety	3.0 [0-5]	5.5 [3-8]	2 [0-5]	0.008
Drowsiness	2.0 [0-4]	2 [0-5]	2 [0-4]	0.79
Appetite	4.0 [1-6]	5 [1-6]	4 [1-6]	0.64
Wellbeing	5.0 [3-7]	7 [5-8]	4 [3-7]	0.05
Dyspnea	8.0 [6-9]	9.5 [7-10]	8 [6-9]	0.01
Constipation	0.0 [0-3]	0 [0-4]	0 [0-3]	0.76
Sleep	5.0 [2-7]	7 [2-9]	4 [2-7]	0.12
Cough	7.0 [4-9]	8 [3-9]	7 [4-9]	0.74

Median values and [interquartile range]. ILD, Interstitial lung disease.

Table S3 Comparison of Edmonton Symptom Assessment System scores among COPD patients stratified by transplant outcome

Domain (median, IQR)	Total Cohort COPD (n=24)	COPD Delisted/Died (n=2)	COPD transplanted (n=22)
Pain	1 [0-2.75]	1 [0-2]	1 [0-3]
Fatigue	6 [4-8]	8 [8-8]	6 [4-8]
Nausea	0 [0-2.5]	0 [0-0]	0 [0-3.25]
Depression	1.5 [0-5]	4 [2-6]	0.5 [0-5]
Anxiety	5 [2-7]	7.5 [7-8]	4.5 [2-7]
Drowsiness	3.5 [1.25-5]	5 [5-5]	3 [1-5]
Appetite	3.5 [2-5]	3 [1-5]	3.5 [2-5]
Wellbeing	5 [4-7]	6.5 [5-8]	5 [3.75-7]
Dyspnea	7 [6-9]	7.5 [6-9]	7 [6-9]
Constipation	1 [0-4]	5 [1-9]	1 [0-4]
Sleep	5 [3-7.75]	7 [5-9]	4.5 [2.75-7.25]
Cough	4 [1-6]	6.5 [6-7]	3 [0.5-5.5]

Median values and [interquartile range]. COPD, Chronic obstructive pulmonary disease; IQR, interquartile range.